GlobeNewswire·Apr 27, 2026, 7:00 AM ET

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Fulcrum Therapeutics presented positive Phase 1b PIONEER trial data for pociredir showing robust fetal hemoglobin induction, improved hemolysis & anemia markers, & encouraging vaso-occlusive crisis reduction trends.
The company plans to initiate a potential registration-enabling trial in the second half of 2026 following FDA feedback expected in the second quarter.
The first patient was dosed in an open-label long-term trial evaluating the safety & durability of response to pociredir for PIONEER participants.
Josh Lehrer, M.D., M.Phil., FACC, an experienced sickle cell disease leader, was appointed to the Board of Directors.
Chief Financial Officer Alan Musso plans to retire later in 2026 but will remain until a successor is named & serve as a consultant to support the transition.
The company ended Q1 2026 with $333.3 million in cash, cash equivalents, & marketable securities, extending its cash runway into 2029.
Research and development expenses for Q1 2026 were $14.1 million, while general and administrative expenses were $8.1 million.
Net loss for the three months ended March 31, 2026, was $18.9 million compared to $17.7 million in the same period of 2025.
Pociredir has been granted Fast Track & Orphan Drug Designation from the FDA for sickle cell disease treatment.
An abstract from the PIONEER trial was accepted for oral presentation at the Foundation for Sickle Cell Disease Research Symposium in June 2026.